Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) Equity Average (2016 - 2025)

Perspective Therapeutics' Equity Average history spans 14 years, with the latest figure at $254.0 million for Q3 2025.

  • For Q3 2025, Equity Average fell 24.13% year-over-year to $254.0 million; the TTM value through Sep 2025 reached $254.0 million, down 24.13%, while the annual FY2024 figure was $182.9 million, 181.81% up from the prior year.
  • Equity Average for Q3 2025 was $254.0 million at Perspective Therapeutics, down from $275.2 million in the prior quarter.
  • Across five years, Equity Average topped out at $334.7 million in Q3 2024 and bottomed at $40.4 million in Q1 2021.
  • The 5-year median for Equity Average is $87.0 million (2023), against an average of $145.8 million.
  • The largest annual shift saw Equity Average skyrocketed 1130.96% in 2021 before it decreased 24.13% in 2025.
  • A 5-year view of Equity Average shows it stood at $65.1 million in 2021, then fell by 13.68% to $56.2 million in 2022, then skyrocketed by 54.84% to $87.0 million in 2023, then surged by 255.93% to $309.6 million in 2024, then decreased by 17.97% to $254.0 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Equity Average are $254.0 million (Q3 2025), $275.2 million (Q2 2025), and $287.7 million (Q1 2025).